Author

M. Qui

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 2 Cancer Biology· 1 Immunology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 4 Approach:experimental assay· 3 Organism:human· 3 Research Focus:cell type annotation· 1 Approach:deep learning· 1 Assay:flow cytometry· 1 Assay:fluorescence / live-cell microscopy· 1 Approach:microscopy & imaging analysis· 1

Frequent Co-Authors

H. Fu· 4 shared Y. Du· 4 shared D. DeRyckere· 2 shared D. K. Graham· 2 shared E. C. Dreaden· 2 shared H. Zecca· 2 shared J. Jain· 2 shared J. M. Kelvin· 2 shared

Activity by Year

2021-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersBioengineering

H. Fu

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Development of a Time-Resolved Fluorescence Resonance Energy Transfer ultra-high throughput screening assay for targeting SYK and FCER1G interaction

Y. Du, D. Wang, V. L. Katis, E. L. Zoeller, M. Qui, A. I. Levey, O. Gileadi, the Emory-SAGE-SGC TREAT-AD Center, H. Fu

This paper develops a time-resolved fluorescence resonance energy transfer (TR-FRET) assay for screening small molecule inhibitors targeting the SYK and FCER1G interaction, identifying hematoxylin as a hit.

bioRxiv · Jun 11, 2024Pharmacology & Toxicology

A multiplexed time-resolved fluorescence resonance energy transfer ultrahigh-throughput screening assay for targeting SMAD4-SMAD3-DNA complex

W. Ouyang, Q. Niu, M. Qui, Y. Du, H. Fu, X. Mo

This paper develops a multiplexed TR-FRET assay to screen small molecule inhibitors targeting the SMAD4-SMAD3-DNA complex, identifying gambogic acid and gambogenic acid as potential hits.

bioRxiv · Jul 15, 2023Cancer Biology

Constitutively synergistic multiagent drug formulations targeting MERTK, FLT3, and BCL-2 for treatment of AML

J. M. Kelvin, J. Jain, A. Thapa, M. Qui, L. A. Birnbaum, S. G. Moore, H. Zecca, R. J. Summers, E. Costanza, B. Uricoli, X. Wang, N. T. Jui, H. Fu, Y. Du, D. DeRyckere, , E. C. Dreaden

The paper develops a nanoscale combination drug formulation targeting MERTK, FLT3, and BCL-2 to treat AML, showing improved synergistic responses in vitro and in patient samples.

bioRxiv · Mar 13, 2023 · PreprintBioengineering

Screening and Development of Constitutively Synergistic Combination Drug Formulations for T Cell Acute Lymphoblastic Leukemia

J. M. Kelvin, D. Y. Zhang, E. K. Williams, S. G. Moore, L. A. Birnbaum, H. Zecca, X. Wang, J. Jain, M. Qui, N. T. Jui, H. Fu, Y. Du, M. L. Kemp, W. A. Lam, D. DeRyckere, , E. C. Dreaden

The paper identifies synergistic drug combinations for T-ALL using high-throughput screens and develops lipid nanoparticle formulations that maintain drug synergy and improve anti-leukemic activity.

bioRxiv · Sep 21, 2022 · PreprintBioengineering

Rapid determination of the wide dynamic range of SARS-CoV-2 Spike T cell responses in whole blood of vaccinated and naturally infected

A. T. Tan, J. M. Lim, N. Le Bert, K. Kunasegaran, A. Chia, M. Qui, N. Tan, W. N. Chia, R. Alwis, Y. Ding, E. E. Ooi, L.-F. Wang, M. I. Chen, B. Young, L. Y. Hsu, , A. Bertoletti

This study evaluates a rapid whole blood test for measuring SARS-CoV-2 Spike-specific T cell responses in vaccinated and infected individuals, finding a wide dynamic range independent of neutralizing antibodies.

bioRxiv · Jun 29, 2021 · PreprintImmunology